Antiviral therapy for hepatitis virus-related hepatocellular carcinoma: current status and challenges

• Main Authors: DONG Jing, JIANG Jiaji
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Clinical Hepatology 2017-07-01
• Series: Linchuang Gandanbing Zazhi
• Online Access: http://www.lcgdbzz.org/qk_content.asp?id=8312

The incidence rate of hepatocellular carcinoma (HCC) is increasing around the world and tends to decrease in East Asia and several regions in China; however, China still has higher incidence rate and mortality rate of HCC than most countries. Studies have shown that long-term antiviral therapy can inhibit HBV replication to a very low level or help patients with HCV infection achieve sustained virologic response, which can further reduce the incidence rate of virus-related HCC. New evidence suggests that compared with nucleos(t)ide analogues, PEG-IFNα has a better effect of secondary prevention. Studies also indicate that interferons play an important role in tertiary prevention of virus-related HCC. This article reviews the epidemiological studies on virus-related HCC in recent years and the role of antiviral therapy in second and tertiary prevention and points out that adequate and effective antiviral therapy is the basis for preventing the development and recurrence of HCC.